Citius Pharma subsidiary Citius Oncology says new LYMPHIR institutional accounts jump 78% Q/Q

Citius Pharma’s majority-owned unit Citius Oncology reported faster early uptake for LYMPHIR in cutaneous T-cell lymphoma.

• New institutional accounts ordering LYMPHIR rose 78% quarter over quarter in the June 30, 2026 quarter; total institutional vial orders increased 31%.
• LYMPHIR reached 42 institutions; Citius Oncology expects more than 20 additional institutions in the current quarter.
• Near-universal payer coverage was cited; initial CTCL market opportunity for LYMPHIR was pegged at more than $400 million.
• Revenue recognition is tied to wholesale orders placed and filled; wholesalers have started reordering as demand increases.